CAD 0.2
(0.0%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 563.4 Thousand CAD | -478.72% |
2022 | 372.4 Thousand CAD | -72.31% |
2021 | 1.34 Million CAD | 548.24% |
2020 | 207.45 Thousand CAD | 455.63% |
2019 | 37.33 Thousand CAD | 123.89% |
2018 | -156.27 Thousand CAD | 0.0% |
2017 | - CAD | 0.0% |
2016 | - CAD | 0.0% |
2015 | - CAD | 0.0% |
2014 | - CAD | 0.0% |
2013 | - CAD | 0.0% |
2012 | - CAD | 0.0% |
2011 | - CAD | 0.0% |
2010 | - CAD | 0.0% |
2009 | - CAD | 0.0% |
2008 | - CAD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | -316.02 Thousand CAD | 153.8% |
2024 Q1 | -609.69 Thousand CAD | -132.12% |
2023 Q3 | -450.14 Thousand CAD | -284.53% |
2023 FY | -1.41 Million CAD | -478.72% |
2023 Q1 | 117.6 Thousand CAD | 310.47% |
2023 Q2 | 243.94 Thousand CAD | 107.43% |
2023 Q4 | -262.67 Thousand CAD | 41.65% |
2022 Q4 | 28.65 Thousand CAD | -87.41% |
2022 Q1 | 31.39 Thousand CAD | -94.84% |
2022 Q2 | 84.87 Thousand CAD | 170.36% |
2022 FY | 372.4 Thousand CAD | -72.31% |
2022 Q3 | 227.48 Thousand CAD | 168.03% |
2021 FY | 1.34 Million CAD | 548.24% |
2021 Q1 | 84.87 Thousand CAD | 7.33% |
2021 Q2 | 291.94 Thousand CAD | 243.98% |
2021 Q3 | 359.17 Thousand CAD | 23.03% |
2021 Q4 | 608.81 Thousand CAD | 69.5% |
2020 FY | 207.45 Thousand CAD | 455.63% |
2020 Q2 | 3155.00 CAD | 116.47% |
2020 Q3 | 124.98 Thousand CAD | 3861.55% |
2020 Q4 | 79.07 Thousand CAD | -36.73% |
2020 Q1 | -19.15 Thousand CAD | -357.84% |
2019 FY | 37.33 Thousand CAD | 123.89% |
2019 Q4 | 7428.00 CAD | 100.83% |
2019 Q1 | 12.13 Thousand CAD | 635.85% |
2019 Q3 | -891.58 Thousand CAD | -198.05% |
2019 Q2 | 909.36 Thousand CAD | 7392.47% |
2018 Q2 | - CAD | 0.0% |
2018 Q1 | - CAD | 0.0% |
2018 FY | -156.27 Thousand CAD | 0.0% |
2018 Q3 | 2147.00 CAD | 0.0% |
2018 Q4 | -2265.00 CAD | -205.5% |
2017 Q2 | - CAD | 0.0% |
2017 Q1 | - CAD | 0.0% |
2017 Q4 | - CAD | 0.0% |
2017 Q3 | - CAD | 0.0% |
2017 FY | - CAD | 0.0% |
2016 Q2 | - CAD | 0.0% |
2016 FY | - CAD | 0.0% |
2016 Q3 | - CAD | 0.0% |
2016 Q4 | - CAD | 0.0% |
2016 Q1 | - CAD | 0.0% |
2015 Q2 | - CAD | 0.0% |
2015 Q4 | - CAD | 0.0% |
2015 FY | - CAD | 0.0% |
2015 Q3 | - CAD | 0.0% |
2015 Q1 | - CAD | 0.0% |
2014 Q4 | - CAD | 0.0% |
2014 Q1 | - CAD | 0.0% |
2014 FY | - CAD | 0.0% |
2014 Q3 | - CAD | 0.0% |
2014 Q2 | - CAD | 0.0% |
2013 FY | - CAD | 0.0% |
2013 Q4 | - CAD | 0.0% |
2013 Q3 | - CAD | 0.0% |
2013 Q2 | - CAD | 0.0% |
2013 Q1 | - CAD | 0.0% |
2012 Q1 | - CAD | 0.0% |
2012 Q4 | - CAD | 0.0% |
2012 Q2 | - CAD | 0.0% |
2012 FY | - CAD | 0.0% |
2012 Q3 | - CAD | 0.0% |
2011 Q2 | - CAD | 0.0% |
2011 Q3 | - CAD | 0.0% |
2011 Q4 | - CAD | 0.0% |
2011 FY | - CAD | 0.0% |
2011 Q1 | - CAD | 0.0% |
2010 Q2 | - CAD | 0.0% |
2010 Q1 | - CAD | 0.0% |
2010 FY | - CAD | 0.0% |
2010 Q4 | - CAD | 0.0% |
2010 Q3 | - CAD | 0.0% |
2009 Q3 | - CAD | 0.0% |
2009 FY | - CAD | 0.0% |
2009 Q1 | - CAD | 0.0% |
2009 Q4 | - CAD | 0.0% |
2009 Q2 | - CAD | 0.0% |
2008 Q3 | - CAD | 0.0% |
2008 Q4 | - CAD | 0.0% |
2008 FY | - CAD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Algernon Pharmaceuticals Inc. | -50.39 Thousand CAD | 1217.919% |
Asep Medical Holdings Inc | -113.74 Thousand CAD | 595.348% |
BetterLife Pharma Inc. | - CAD | -Infinity% |
BioVaxys Technology Corp. | - CAD | -Infinity% |
ChitogenX Inc. | -42 Thousand CAD | 1441.45% |
Defence Therapeutics Inc. | -90.92 Thousand CAD | 719.648% |
Entheon Biomedical Corp. | 250.32 Thousand CAD | -125.073% |
Gemina Laboratories Ltd. | -93.36 Thousand CAD | 703.428% |
Glow Lifetech Corp. | -505.62 Thousand CAD | 211.428% |
Lexston Life Sciences Corp. | -26.39 Thousand CAD | 2234.61% |
Pharmala Biotech Holdings Inc. | 454.09 Thousand CAD | -24.072% |
Doseology Sciences Inc. | -36.08 Thousand CAD | 1661.382% |
MYND Life Sciences Inc. | -332.99 Thousand CAD | 269.197% |
Nova Mentis Life Science Corp. | 25.4 Thousand CAD | -2117.709% |
PharmaTher Holdings Ltd. | -711.00 CAD | 79341.772% |
PreveCeutical Medical Inc. | -9856.00 CAD | 5816.406% |
Telescope Innovations Corp. | 595.39 Thousand CAD | 5.373% |